1 **Multi-omic association study identifies DNA methylation-mediated genotype and smoking**

2 **exposure effects on lung function in children living in urban settings**

3

34 **ABSTRACT**

50 **AUTHOR SUMMARY**

51 Lung function is determined by both genetic and environmental factors. Impairment of lung function can 52 result from harmful environmental exposures in early life, which disproportionally affect children living 53 in low-income, urban communities. However, most genetic association studies of lung function have been 54 performed in adults and without regard for socioeconomic status. Therefore, genetic risk factors 55 discovered to date may not reflect those most relevant to high-risk populations. In this study, we sought to 56 identify genetic variants correlated with lung function in a multiethnic cohort of children living in low-57 income, urban neighborhoods and analyze how tobacco smoke exposure may influence any genetic 58 effects. We discovered a common genetic variant associated with lower lung function in this population, 59 and we found that the association was mediated by nearby epigenetic changes in DNA methylation, which 60 were in turn correlated with smoking exposure. We then identified a nearby gene, *PPP1R13B*, which is 61 known to aid in the deactivation of damaged cells, whose expression in airway cells aligned with these 62 genetic and epigenetic effects. This study reveals a potential mechanism through which genetic risk and 63 environmental exposures can affect airway development, perhaps leading to interventions that can help 64 reduce the burden of asthma in socioeconomically disadvantaged children.

65 **INTRODUCTION**

66 Reduced lung function is a hallmark of asthma and chronic obstructive pulmonary disease (COPD). Lung 67 function measures, such as forced expiratory volume in one second $(FEV₁)$ and forced vital capacity 68 (FVC), are strong predictors of future all-cause mortality [1-6]. Airway obstruction often begins in early 69 life [7-10], with lower lung function in infancy being a risk factor for the development of asthma in 70 childhood [11] and COPD in late adulthood [12].

71 Genetic factors contribute to differences in lung function among individuals, with heritability 72 estimates ranging from 0.50 for $FEV₁$ to 0.66 for $FEV₁/FVC$ ratio [13]. The many genome-wide 73 association studies (GWAS) of lung function measures [14-25] have implicated pathways related to lung 74 development [20,26-28], inflammation [26], and tissue repair [29], among others [29]. Lung function is 75 also affected by environmental exposures, such as smoking [30-32] and air pollution [33], which can 76 disrupt airway development in early life, increasing the risk of childhood asthma and perhaps other 77 chronic obstructive diseases [8-12,34,35]. For example, exposure to second hand smoke in utero and 78 through childhood is associated with increased risk of childhood asthma [36], lower lung function in 79 adolescence [37], and larger declines in lung function later in life [38,39]. Such adverse exposures are 80 known to alter the epigenetic landscape in exposed individuals [40,41], potentially mediating downstream 81 biological effects [42-44] and modifying genetic associations with lung function [45,46].

82 Environmental risk factors disproportionally affect socioeconomically disadvantaged children, 83 particularly those living in urban environments [47,48]. In fact, socioeconomic effects contribute to 84 disparities in lung health [49], including the higher burden of chronic respiratory disease among Black 85 and Hispanic children compared to non-Hispanic white children [49-52]. Most genetic association studies 86 of lung function, however, have been limited to adults of European descent. Therefore, genetic risk 87 factors discovered to date may not reflect those most relevant to high-risk populations, which can further 88 exacerbate health disparities [53,54]. Identifying genetic variants and epigenetic variation associated with 89 lung function in high-risk, multiethnic, pediatric populations may provide more direct insights into the 90 early development of impaired lung function.

113 **Table 1. Demographic characteristics of sequenced APIC and URECA participants.**

Results are presented as counts and percentages or as means with standard deviations. Missing data were not included in percentage calculations. Ages for URECA correspond to the year the genome-wide association study lung function data were collected. *Caretaker smoking status in URECA was collected 117 at age 10. APIC: Asthma Phenotypes in the Inner City; BMI: body mass index; FEV₁: forced expiratory 118 volume in one second; FEV₁/FVC: ratio of FEV₁ to forced vital capacity; HS: high school; URECA: Urban Environment and Childhood Asthma.

121 The sequenced cohort included 696 (67%) participants who self-identified as non-Hispanic Black

122 and 258 (25%) who self-identified as Hispanic (**Table 1**). Principal component and admixture analyses

123 using genotypes were used to characterize the ancestry of the participants (**Fig 1**). This revealed that the

¹²⁰

124 genetic ancestry of our sample was 66% African, 26% European, 7% Native American, and 1% East

- 125 Asian. The cohort was 54% male and included 681 (66%) children diagnosed with asthma (**Table 1**).
- 126

Fig 1. Ancestry composition of sequenced APIC & URECA participants. A) The top two principal components (PCs) of ancestry are plotted for sequenced APIC & URECA participants, colored by self-identified race/ethnicity, along with the four ancestral reference populations used for determining ancestry. NS= not specified. B) The proportion of genetic variance explained by each of the top 10 PCs. C) The relative values of the top 10 PCs are plotted for each sample, colored by reference population. D) The estimated proportion of admixture from each ancestral population is shown for each sequenced APIC
133 & URECA participant. Each vertical line corresponds to one sample. 1KG, 1000 Genomes project; HGDP, & URECA participant. Each vertical line corresponds to one sample. 1KG, 1000 Genomes project; HGDP, Human Genome Diversity Project; YRI, Yoruba in Ibadan, Nigeria; CEU, Utah residents with Northern and Western European ancestry; CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan; NAT, Native Americans from HGDP; EAS, East Asian ancestry; AFR, African ancestry; EUR, European ancestry.

138

139 Using the WGS variant calls for 14.1 million variants with minor allele frequency (MAF) \geq 0.01,

140 we performed a GWAS of two lung function traits: FEV_1 (% predicted) and FEV_1 FVC (Z-scores),

141 measured between ages 5-17 (**Table 1**, **S2 Fig**), adjusting for age, sex, asthma diagnosis, the first 10

142 principal components (PCs) of ancestry, and sample relatedness using a linear mixed model [58]. The

143 FEV₁ GWAS included 896 participants from APIC ($n=504$) and URECA ($n=392$), and the FEV₁/FVC

144 GWAS included 886 participants from APIC (n=497) and URECA (n=389). The genomic control factor,

145 λ_{GC} , for both GWAS results was 1.02 (**S3 Fig**), indicating adequate control for population stratification.

146 We identified one locus on chromosome 14q32.33 that was associated with $FEV₁$ at genome-wide

147 significance ($p < 2.5x10^{-8}$); no other variants were associated with $FEV₁$ and no variants were associated

148 with FEV₁/FVC at genome-wide levels of significance (Fig 2). The FEV₁ locus on chromosome 14

149 consisted of a 200 kb region of associated variants in high linkage disequilibrium (LD) across the *TDRD9*

150 (Tudor Domain Containing 9) gene (**Fig 3**, **S2 Table**). The minor allele at the lead SNP (rs10220464;

- 151 MAF=0.30) was significantly associated with lower $FEV_1 (p=2.4x10^{-9}; \beta_z = -0.31, 95\%$ confidence
- interval (CI)= -0.41- -0.21) and nominally associated with lower FEV₁/FVC (p=1.1x10⁻³; β_z= -0.17, 95%

153 CI= -0.28- -0.07). Fine-mapping analysis at this locus (chr14:103.7-104.3Mb) revealed one 95% credible

154 set of effect variables consisting of 59 SNPs, with rs10220464 having the highest individual posterior

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.06.24.22276830;](https://doi.org/10.1101/2022.06.24.22276830) this version posted November 4, 2022. The copyright holder for this preprint

- 155 inclusion probability among them (**S4 Fig**). We did not detect any significant differences in rs10220464
- 156 association effect size by ancestry or asthma status or study for FEV₁ (Fig 4). Furthermore, the *TDRD9*
- 157 locus remained the only genome-wide significant association when the two GWAS were performed
- 158 without adjustment for asthma status (**S5 Fig**). The overall effect size correlations between asthma-
- 159 adjusted and unadjusted GWAS results were $r=0.981$ for $FEV₁$ and $r=0.954$ for $FEV₁/FVC$.
- 160

161 **Fig 2. Genome-wide association results.** GWAS Manhattan plots for A) FEV₁ and **B**) FEV₁/FVC ratio. The horizontal red line indicates genome-wide significance (p ≤ 2.5x10⁻⁸). The dotted horizontal blue line 163 indicates p=1x10⁻⁵. Variants colored in green are in previously identified GWAS loci [23]. FEV₁, forced indicates p=1x10⁻⁵. Variants colored in green are in previously identified GWAS loci [23]. FEV₁, forced 164 expiratory volume in one second; FEV₁/FVC, ratio of FEV₁ to forced vital capacity.

165 166

Fig 3. FEV₁-associated variants on chromosome 14q32.33. FEV₁ association results are shown at the *TDRD9* gene locus. Each variant is plotted according to its position and -log₁₀ p-value, colored by linkage disequilibrium to the lead variant, rs10220464, within the sample. Candidate cis-Regulatory Elements (cCREs) from ENCODE [59] are also shown for the region. The inset panel in the upper right shows the 171 distribution of adjusted FEV_1 values by rs10220464 genotype. FEV_1 , forced expiratory volume in one 172 second; MAF, minor allele frequency; EnhD, distal enhancer-like signature; CTCF, CCCTC-binding factor sites; enhP, proximal enhancer-like signature; prom, promoter-like signature; K4m3, trimethylation of histone H3 at lysine 4.

175 176

Fig 4. Rs10220464 effect size heterogeneity. A forest plot of the associations between rs10220464 and FEV1 (% predicted) are shown for distinct sub-cohorts distinguished by self-identified race/ethnicity, study, 179 and asthma status. β_z , the association effect size between the rs10220464 allele count and the adjusted and normalized FEV₁ (% predicted) values. FEV₁, forced expiratory volume in one second; N, total number of individuals included in the association test; MAF, minor allele frequency within the sub-cohort; 182 P, the association p-value.

183

191 0.05- 0.50; p=0.020) for FEV_1 and 0.42 (95% CI=0.25- 0.56; p=4.2x10⁻⁶) for FEV_1/FVC .

192

193 **Lung function risk alleles are associated with DNA methylation at the** *TDRD9* **locus in airway** 194 **epithelial cells** 195 The majority of complex trait-associated variants exert effects by altering gene regulatory networks [60- 196 62]. These changes are often marked by quantitative differences in DNA methylation levels [63-65]. We 197 therefore investigated correlations between the FEV₁-associated allele at *TDRD9* and DNA methylation at 198 the locus in upper airway (nasal) epithelial cells (NECs) from URECA children at age 11 (n=286). We 199 tested for associations between the FEV_1 genotype, as tagged by rs10220464, and DNA methylation 200 levels at 796 CpG sites within 10 kb of any *TDRD9* locus variants associated with $FEV₁$ at $p<1x10^{-5}$ 201 (n=82 variants). The rs10220464 genotype was an meQTL for 5 CpG sites at an FDR <0.05 (**S3 Table**). 202 DNA methylation levels at only one of these CpG sites, cg03306306 (p=2.3 x10⁻⁴; β=0.07, 95% CI=0.03-203 0.10; **Fig 5a**), was also significantly associated with FEV₁ at age 10 in URECA ($p=0.011$; $\beta = -11.48$, 95% 204 CI= -20.27- -2.69; **Fig 5b**). The rs10220464 genotype accounted for 4.7% of residual variation in 205 cg03306306 methylation, and cg03306306 methylation explained 2.4% of residual variation in FEV1. 206
207 **Fig 5. Genotype and FEV₁ associations with DNA methylation.** DNA methylation levels at 208 cg03306306 are shown by rs10220464 genotype and FEV₁ measures are plotted against cg03306306 209 methylation levels in NECs at age 11 (A, B), and PBMCs at age 7 (C, D) from URECA. FEV₁, forced 210 expiratory volume in one second; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear 211 cells; URECA, Urban Environment and Childhood Asthma study. 212 213 We then analyzed cg03306306 methylation in PBMCs collected at age 7 (n=169) [66] from 214 URECA children to evaluate whether the genotype and lung function associations observed in NECs were 215 shared with blood cells. In PBMCs, we observed no correlation between the rs10220464 risk allele and 216 cg03306306 methylation (**Fig 5c**), nor was there an association between cg03306306 methylation and 217 FEV1 (**Fig 5d**). These results indicate that cg03306306 methylation dynamics in the airway epithelium are 218 not present in peripheral blood cells. 219

273 **Fig 7.** *PPP1R13B* **gene expression in NECs.** *PPP1R13B* gene expression in NECs at age 11 are 274 plotted against A) rs10220464 genotype (n=324) and B) DNA methylation at cg03306306 in NECs at age 275 11 (n=254). NECs, nasal epithelial cells; CPM, counts per million.

- 276
- 277 The transcription start site of *PPP1R13B* resides 87 kb from rs10220464 and 152 kb from
- 278 cg03306306, suggesting long-range interactions between the FEV1-associated genotype and the promoter
- 279 of *PPP1R13B*. To determine whether any of the FEV₁-associated GWAS variants at the *TDRD9* locus
- 280 resided in regions that physically interacted with the promoters of *cis*-genes, we evaluated chromatin
- 281 interactions in lower airway (bronchial) epithelial cells (BECs) [72], assessed by promoter-capture Hi-C.
- 282 Forty-two of the GWAS variants resided in regions that interacted with the promoters of 9 different genes
- 283 expressed in NECs (**Fig 8**; **S5 Table**). The gene most frequently mapped to these variants was
- 284 *PPP1R13B*, with 15 variants located in 3 different interaction loops. Moreover, the strongest observed
- 285 interaction was between a region containing 4 FEV₁-associated variants and the *PPP1R13B* promoter
- 286 (CHiCAGO score = 9.38; **S5 Table**), suggesting that this region is an enhancer for *PPP1R13B*
- 287 expression. This putative enhancer region is located just 2.21 kb from cg03306306.
- 288
289

289 **Fig 8. Promoter-enhancer interactions at** *TDRD9* **locus in nasal epithelial cells.** Promoter-to-290 enhancer chromatin interactions captured by Hi-C in nasal epithelial cells from URECA at age 11 are 291 displayed as grey arcs. SNPs associated with $FEV_1 (p<1x10^{-5})$ are marked by blue lines in the top row 292 according to their genomic position on chromosome 14. The lead $FEV₁$ SNP, rs1022464, is highlighted in 293 yellow. CpG sites associated with rs1022464 (FDR<0.05) are displayed as green markers below the 294 genes, with cg03306306 highlighted in green. Chromatin Interactions containing SNPs associated with FEV1 (p<1x10-5 295) are highlighted in blue. Magenta arcs highlight interactions between the *PPP1R13B* 296 promoter and regions containing FEV_1 SNPs and/or rs1022464-associated CpG sites. FEV₁, forced 297 expiratory volume in one second; SNPs, single nucleotide polymorphisms; meQTL, methylation 298 guantitative trait locus; pcHi-C, promoter capture Hi-C.

- 299
- 300
- 301 **Summary of study associations**
- 302 The associations between the *TDRD9* risk allele, cg03306306 DNA methylation in NECs, smoking
- 303 exposure, *PPP1R13B* gene expression, and FEV₁ (% predicted) reported in this study are summarized in
- 304 **Fig 9**.

305

506 • Fig 9. Summary of study associations. The *TDRD9* locus was significantly associated with FEV₁ (%) predicted) in the APIC and URECA cohorts. This association was partially mediated by DNA methylation at the cg03306306 CpG site in *TDRD9* in NECs, which was also significantly associated with environmental tobacco smoke exposure*.* The TDRD9 risk allele and DNA methylation were both significantly associated with *PPP1R13B* gene expression, but *PPP1R13B* gene expression was not significantly correlated with FEV₁ itself. Unidirectional arrows represent inferred causality.

- 312 313
- 314

315 **DISCUSSION**

316 Using whole-genome sequence variant calls in an asthma-enriched cohort of predominantly African-

317 American children raised in urban environments, we identified a genotype at the *TDRD9* locus associated

318 with lower FEV_1 % predicted. This genotype effect was partially mediated by DNA methylation in airway

319 epithelial cells, which were also correlated with smoking exposure. Data from RNA-sequencing and

 320 promoter-capture Hi-C in airway epithelial cells suggested that these $FEV₁$ -associated genetic and

321 epigenetic variations influence the expression of the *PPP1R13B* gene through long-range interactions.

322 The *PPP1R13B* gene encodes a protein that promotes apoptosis, a form of programmed cell

323 death, via its interaction with the tumor suppressor p53 and is often referred to by its alias ASPP1

324 (apoptosis-stimulating protein of p53 1) [73]. In response to oncogenic stress, PPP1R13B translocates to

325 the nucleus, where it enhances the transcriptional activity of p53 on specific target genes relevant to

326 apoptosis [74,75]. Exposure to smoking and fine particulate matter induces epithelial apoptosis in the

327 lung via p53 [76-78]. PPP1R13B may also promote apoptosis in a p53-independent manner by inhibiting

328 autophagy in response to upregulation by EGR-1 (early growth response protein 1) [79]. EGR-1 mediates

329 stress-induced proinflammatory responses in the airway epithelium and contributes to the pathogenesis of

330 COPD [80-85]. Within the lung, *PPP1R13B* is indeed predominantly expressed in epithelial cells,

331 particularly in alveolar type 2 cells, and less so in immune cells and fibroblasts [86,87]. However, Cheng

332 and colleagues studied PPP1R13B function in lung fibroblasts and found that it was upregulated

 333 following $SiO₂$ exposure, where it promoted fibroblast proliferation and migration through endoplasmic

334 reticulum stress and autophagy pathways [88]. Overall, these studies suggest that *PPP1R13B* plays a key

335 role in maintaining tissue homeostasis by regulating apoptosis and autophagy in response to 336 environmental stimuli [74,89,90]. The specific function(s) of this gene in the airway epithelium and its 337 potential impact on the development of airway obstruction remain to be elucidated. *PPP1R13B* 338 expression in airway epithelial cells at age 11 was not directly associated with lung function or urine 339 cotinine levels in the URECA children, but the cofactors of this gene [79,91] have been found previously 340 to be upregulated in smokers with COPD [81,92]. Given its association with lung function alleles in our 341 study, its expression in the airway epithelium, and its purported functions in autophagy and apoptosis 342 pathways, additional study of *PPP1R13B* in lung and airway development is warranted, particularly in the 343 context of adverse environmental stimuli, many of which are enriched in low-income urban 344 environments. 345 In NECs, *PPP1R13B* gene expression was significantly associated with DNA methylation levels 346 at the cg03306306 CpG site in *TDRD9*. Methylation at the *TDRD9* locus was previously reported to 347 correlate with specific environmental exposures [67,68,93] and with *TDRD9* expression in blood [67,94]. 348 *TDRD9* is lowly expressed in the lung but is detected in alveolar macrophages and in monocytes [86,87]. 349 Interestingly, the gene was among the most differentially expressed genes in alveolar macrophages in 350 smokers relative to non-smokers [95], and its knockdown in TDRD9*-*expressing lung carcinomas resulted 351 in increased apoptosis [96]. Its expression was not correlated with the rs10220464 genotype in URECA 352 NECs or PBMCs, but rs10220464 is an eQTL for *TDRD9* expression in whole blood in GTEx data [97], 353 with the minor allele associated with lower *TDRD9* expression. Although evidence from this study points 354 to *PPP1R13B* in the airway epithelium, we can't exclude the possibility that *TDRD9* or other genes could 355 contribute to the locus' influence on lung function via other tissues. 356 The correlations of FEV1 and rs10220464 with cg03306306 methylation and *PPP1R13B* 357 expression in NECs were absent in PBMCs. Although global DNA methylation patterns between tissues 358 are highly correlated [98], tissue-specific differentially methylated regions are more likely to be 359 functional, particularly if they are positively correlated with gene expression [99]. The *TDRD9* locus has 360 not been identified in epigenome-wide association studies of lung function [44,100-104], but these

361 measured DNA methylation from blood, which may be an insufficient proxy for methylation in the lungs 362 [105]. Indeed, previous studies have found that DNA methylation profiles in NECs are significantly more 363 predictive of pediatric asthma than those in PBMCs [106,107]. Furthermore, epigenetic biomarkers can 364 change with age. For example, epigenetic markers for lung function in adults do not replicate in children 365 [101].

366 The FEV1 association signal at the *TDRD9* locus included many variants in high LD across a 200 367 kb region that could be independently contributing to function. Some of the variants lie in different long-368 range enhancers [59]. It is also possible that one or more correlated variants were not included because 369 they failed quality control standards. In addition, due to the limited sample size of the WGS cohort, we 370 excluded rare variants (MAF<0.01) from consideration, which could contribute to the signal at this locus.

371 Additional functional studies are needed to identify the causal variant(s) and full mechanism of action.

 372 If increased methylation at cg03306306 leads to lower $FEV₁$ in response to environmental 373 stressors, one might expect to see interaction effects with smoking exposure on $FEV₁$. We did not detect 374 any such interactions, although our analyses in that regard were likely underpowered given our observed 375 effects and sample sizes [36]. Furthermore, because this study was limited to children living in low-376 income urban neighborhoods, environmental risk factors are likely to be more prevalent than in the 377 general population [55-57]. Additionally, such exposures are not necessarily ubiquitous across all the 378 different neighborhoods and communities represented in this sample, and although environmental tobacco 379 smoke exposure was examined and the socioeconomic range represented in this study is relatively 380 narrow, there could be relevant environmental factors that were not considered.

381 To infer causality, Mendelian randomization and mediation analyses rely on assumptions that are 382 often difficult to empirically verify. For the Mendelian randomization analysis, we identified instrumental 383 variants associated with the intermediate cg03306306 that were not independently associated with the 384 outcome, FEV₁. However, because these variants were selected from the same dataset that the outcome 385 testing was performed in, they were susceptible to bias from winner's curse [108]. To mitigate the 386 potential impact from this effect and from weak instruments, we performed a secondary analysis in which

387 we combined the instrumental variants into a single, unweighted score. For the mediation analysis, 388 unmeasured confounding can invalidate direct and indirect effect estimates [109]. To protect against such 389 bias, we systematically tested for confounding associations with additional environmental measures 390 available in APIC and URECA (**Materials and Methods**). Nonetheless, there may still exist unknown 391 confounding factors that were not measured. Ultimately the results of the Mendelian randomization and 392 mediation analyses indicate that methylation at cg03306306 in NECs mediated the rs10220464 genotype 393 effect on FEV_1 , but there was residual correlation between rs10220464 and FEV_1 , signifying that the 394 genotype effect was only partially mediated by cg03306306.

395 Another limitation of our study was the relatively small size for a GWAS. This likely contributed 396 to the lack of statistically significant replication for previously identified lung function loci [23], 397 considering that the observed effects were correlated with results of prior GWAS. However, the APIC 398 and URECA cohorts represent understudied, high-risk, pediatric populations that likely harbor distinct 399 genetic and environmental risk factors compared to older, primarily European ancestry cohorts included 400 in previous GWAS of lung function [14-20,23]. The findings of this study have yet to be replicated in an 401 independent cohort, and should therefore be considered preliminary; however, it is possible that these 402 associations would differ in populations with dissimilar ancestry, age, exposures, and/or asthma risk. 403 There are additional caveats to consider when interpreting our findings. First, this study 404 integrated data from two cohorts with different recruitment criteria, asthma definitions, and ancestral 405 compositions. Furthermore, most of the analyses beyond the GWAS were limited to subsets of the 406 URECA participants. However, we did not observe significant genetic effect heterogeneity for 407 rs10220464 by study, asthma status, or ancestry. To control for potential population stratification, we 408 used the first ten PCs of ancestry to adjust lung function values and then included the ancestry PCs as 409 fixed effects in the GWAS models (**Materials and Methods**). The linear mixed models also included a 410 genetic relatedness matrix as a random effect to account for residual population structure. Because 411 children with asthma have lower lung function overall (**Table 1**) and their lung function may be more

412 affected by environmental exposures [110-112], we adjusted for asthma status in the GWAS, as in

413 previous GWAS [113-116]. The likelihood of discovering lung function variants with consistent effects in 414 asthmatics and non-asthmatics was thereby increased, although genetic determinants of lung function may 415 differ by asthma status [117]. Furthermore, adjusting for disease status could potentially introduce 416 collider bias [118]. The significant genotype effect at the *TDRD9* locus, however, remained the only 417 genome-wide-significant association when asthma was excluded as a covariate, and adjustment for 418 asthma did not substantively alter the mediation results. Second, some of the analyses used data collected 419 at different timepoints. For example, most of the urine cotinine and spirometry measures were collected at 420 age 10, but the samples used for the NEC DNA methylation and RNA-seq analyses were collected at age 421 11. Because DNA methylation and gene expression can change over time [40,119-121], their values at 422 age 11 may not be fully representative of exposures at age 10. Finally, the promoter-capture Hi-C data 423 were from lower airway (bronchial) epithelial cells, whereas the DNA methylation and RNA-seq data 424 were generated from upper airway (nasal) epithelial cells. Although there are transcriptomic differences 425 between epithelial cells from each compartment, their respective profiles are highly correlated [122-126], 426 and the use of NECs as a proxy for the lower airway epithelium has been validated for both gene 427 expression and epigenetic studies [124-127]. 428 Our study identified a novel avenue through which genetic risk and environmental exposures

429 could affect the airways of children raised in low-income urban neighborhoods. Further research into this 430 pathway may yield mechanistic insights into the early development of impaired lung function, perhaps 431 leading to interventions that can help reduce the high incidence and morbidity of chronic respiratory

432 diseases in socioeconomically disadvantaged children.

433

434 **MATERIALS AND METHODS**

435 **Study Population and Phenotypes**

436 We analyzed samples and phenotypes from two National Institutes of Allergy and Infectious 437 Diseases (NIAID)-funded asthma studies conducted by the Inner-City Asthma Consortium (ICAC)[128]: 438 the Asthma Phenotypes in the Inner City (APIC) study[55,56] and the Urban Environment and Childhood 439 Asthma (URECA) birth cohort study [57]. The APIC study was a 1-year, prospective, epidemiological 440 investigation of children and adolescents with asthma (ages 6-17) living in low-income areas (≥20% of 441 residents below poverty level) in nine U.S. cities (Baltimore, MD; Boston, MA; Chicago, IL; Cincinnati, 442 OH; Dallas, TX; Denver, CO; Detroit, MI; New York, NY; Washington, DC). The APIC participants 443 were required to have a diagnosis of asthma by a physician and to have had at least two episodes 444 requiring bronchodilator administration within the past year [55]. The URECA study enrolled pregnant 445 women living in low-income areas of four U.S. cities (Baltimore, MD; Boston, MA; New York, NY; St. 446 Louis, MO) who reported that either or both parents of the index pregnancy had a history of asthma or 447 allergic diseases [57]. This prospective, longitudinal study followed each child through adolescence, 448 periodically collecting samples and clinical and environmental exposure data. Institutional review board 449 approval was received from all participating sites, and written informed consent was obtained from legal 450 guardians of all participating children, who also assented.

451 Lung function was assessed using spirometry. Lung function measures used in this study for 452 APIC participants were taken at the study entry visit (V0). For URECA, measurements from age 10 were 453 used when available; otherwise, the most recent measurement after age 5 was used (**S6 Table**). Asthma 454 status was assigned according to study-specific criteria. For APIC, asthma was defined by a doctor's 455 diagnosis of asthma and short-acting beta-agonist use in the year prior [55]. For URECA, asthma status 456 was determined either by doctor diagnosis, lung function reversibility, or symptom recurrence [129]. The 457 2012 Global Lung Initiative reference equations [130] were applied to generate percent predicted 458 estimates for FEV_1 and Z-scores for FEV_1/FVC ratio. Urine cotinine levels were measured using NicAlert 459 immunochromatographic assays, which report results on a scale of 0-6 according to different cotinine

464

465 **Whole-Genome Sequencing and Data Processing**

466 DNA was extracted from peripheral blood (APIC, URECA) or cord blood (URECA) and quantified using 467 an Invitrogen Qubit 3 Fluorometer. DNA quality was assessed using the Thermo Scientific NanoDrop 468 One spectrophotometer and confirmed using an Agilent TapeStation system. DNA was processed in 469 batches of 60 using the Illumina Nextera DNA Flex library prep kit with unique dual adaptors. Each set of 470 60 libraries was sequenced over two NovaSEQ S4 flowcells. Whole-genome sequencing was performed 471 by the University of Chicago Genomics Facility using the Illumina NovaSEQ6000, which generated 150 472 bp paired-end reads. Sequencing data processing followed the Broad Institute's Genome Analysis Toolkit 473 (GATK) best practices for germline short variant discovery, as implemented in the harmonized pipeline 474 used by the New York Genome Center for TOPMed [132,133]. Reads were aligned to the GRCh38 475 human reference genome (including alternate loci and decoy contigs) using BWA-MEM (Burrows-476 Wheeler Aligner; v0.7.17). Aligned reads further underwent duplicate removal (Picard MarkDuplicates; 477 v2.8.1) and base quality score recalibration (GATK BaseRecalibrator; v3.8) against known sites 478 (dbSNP138, known indels, and Mills and 1KG gold standard indels) provided in the GATK resource 479 bundle. Read alignment metrics were calculated using Picard CollectWgsMetrics (v2.8.1) for all aligned 480 reads and for aligned reads with base quality and mapping quality \geq 20. DNA contamination levels were 481 estimated using VerifyBamID2 (v1.0.6) [134]. Samples with estimated DNA contamination >0.05 were 482 removed from consideration. Samples with poor coverage (<50% of the genome with ≥20x depth) were 483 also removed from further consideration. To identify potential sample swaps, WGS samples were 484 validated using independent genotyping arrays.

485

486 **QC Array for Sample Validation**

487 To identify potential WGS sample swaps, we independently genotyped the APIC and URECA 488 participants using the Illumina QC Array-24 BeadChip. SNPs were tested for Hardy-Weinberg 489 Equilibrium (HWE) within each self-identified ancestry group using the chi-square test and removed if 490 they deviated from HWE (Bonferroni-adjusted p<0.05) within at least one ancestry. SNPs with call rates 491 <0.98 were also removed. Samples with total variant call rates <0.95 were not used. Array data with 492 incorrect or indeterminate sex according to X-chromosome heterozygosity rates (Plink v1.90) were also 493 not used [135]. For fourteen of the sequenced URECA samples, we used results from the Illumina 494 Infinium CoreExome+Custom array for sample validation, which were generated and controlled for 495 quality as described by McKennan and colleagues [136]. WGS and array genotypes were tested for 496 concordance using VerifyBamID (v1.1.3) [137]. WGS samples that were not validated with array data 497 were not included in genetic analyses (n=2).

498

499 **Variant Calling and Quality Control**

500 Variant calls were generated using GATK HaplotypeCaller (v4.1.3.0), accounting for contamination 501 estimates, for single nucleotide variants and short insertions, deletions, and substitutions. Sample 502 genotypes were joined using GATK GenomicsDBImport and GenotypeGVCFs over the genomic 503 intervals defined in the GATK WGS calling region interval list provided in the GATK resource bundle. 504 Genotypes with read depth (DP) <10 or quality scores (GQ) <20 were set as missing. Sites with ≥ 0.1 505 missingness were then removed from consideration. Variants with minor allele frequencies >0.05 were 506 tested for accordance with HWE, accounting for population structure [138]. Sites with common variants 507 that deviated from structural HWE ($P<1x10^{-6}$) were removed from consideration. Sites with quality by 508 depth ratios (QD) <4 or >34 were also removed, as we observed declines in variant transition/transversion 509 (TS/TV) ratios beyond these bounds (**S13 Fig**). Variant site quality was further evaluated using machine-510 learning-based Variant Quality Score Recalibration (VQSR). First, SNPs were modeled using GATK 511 VariantRecalibrator (v4.1.3.0) with Hapmap 3 and with Omni 2.5M SNP chip array as truth resources,

536

537 **Quantitative Trait Association Testing**

538 Quantitative traits were adjusted for covariates and normalized using a two-stage approach [148,149]. 539 First, each trait was regressed on age, sex, asthma status, and the first 10 PCs of ancestry. The residuals 540 were then rank-normalized using an inverse normal transformation. In the second stage, the normalized 541 residuals were considered outcome variables in the GWAS, adjusting for the same covariates as in the 542 first stage. Genome-wide association testing was performed for all high-quality common variant calls 543 (MAF≥0.01) using a linear mixed model, as implemented in GEMMA [58], with subject relatedness 544 included as a random effect. Individuals who were not evaluated for asthma at ages 7 or 10 (n=127) were 545 excluded from trait association testing. The threshold we applied for genome-wide significance was 546 $P\leq 2.5x10^{-8}$, based on a $5x10^{-8}$ GWAS threshold and further accounting for two tests. To identify potential 547 collider bias introduced by adjusting for asthma status, we repeated the GWAS without accounting for 548 asthma status in either covariate-adjustment stage.

549 Fine-mapping analysis was conducted using SuSiE (SusieR R package v0.12.27) [150]. SuSiE 550 applies a form of Bayesian variable selection in regression using iterative Bayesian stepwise selection to 551 identify "credible sets" of variables. Each credible set has a 95% probability of containing at least one 552 causal effect SNP. Prior to running SuSiE, we regressed asthma, age, sex, and ancestry PCs 1-10 from the 553 genotype matrix and outcome vector (the normalized FEV_1 residuals).

554 To explore whether there was lead-SNP effect heterogeneity by ancestry, study, or asthma status, 555 we performed additional single-SNP quantitative trait association tests within several different sub-556 cohorts and introduced interaction effects into our models. For ancestry, we performed separate 557 association tests in each of the Black, Hispanic, and white populations, according to self-identified 558 race/ethnicity. We then tested for genotype-by-ancestry interaction effects across APIC and URECA by 559 using admixture proportions as covariates in our models, in lieu of ancestry PCs, and including an 560 interaction term with the lead SNP for each continental ancestry group in turn. We tested these interaction 561 effects using the --gxe argument in GEMMA in four separate models (one for each ancestry). To 562 determine whether there was effect heterogeneity by study (APIC vs. URECA), we performed separate 563 association tests in each study and also tested the association across APIC and URECA with the addition

564 of a study covariate and a genotype-by-study interaction term. For asthma status, we performed separate 565 association tests in the asthmatics and non-asthmatics and tested a genotype interaction term with asthma 566 status.

567

568 **DNA Methylation Analysis**

569 DNA from NECs was collected at age 11 from 287 URECA participants and assessed for genome-wide

570 methylation patterns using the Illumina Infinium Human Methylation EPIC Beadchip. DNA methylation

571 levels from PBMCs at age 7 in URECA were collected and processed as previously described [66].

572 MeQTL analysis was performed using Matrix eQTL [151]. NEC DNA methylation levels were adjusted

573 globally for sex, array, plate, collection site, DNA concentration, percent ciliated epithelial cells, percent

574 squamous cells, and ancestry PCs 1-3. Principal components analysis was then performed on the residual

575 methylation levels, and the first three PCs were included as covariates in the meQTL association

576 tests. Additional methylation PCs were not included in association tests, as they were significantly

577 correlated with asthma phenotypes. Associations with FDR-adjusted P<0.05 were considered significant.

578 MeQTL analysis with the PBMC data included sex, collection site, plate, ancestry PCs 1-3, and eight

579 latent factors [152] (protecting for FEV_1 at age 7) as covariates.

580 To test CpG site methylation associations with lung function in NECs, we performed linear

581 regressions on the most recent FEV₁ measures, with age, sex, ancestry PCs 1-3, and methylation PCs 1-3

582 as covariates. For the PBMC analysis, we set FEV_1 at age 7 as the dependent variable, with sex, collection

583 site, plate, ancestry PCs 1-3, and latent factors included as covariates.

584 For association testing with smoking exposures, we ran linear regressions for DNA methylation 585 and lung function in NECs and PBMCs, as described above, with the addition of cotinine concentrations 586 as a predictor. We further tested for smoking-by-genotype interaction effects on DNA methylation and 587 lung function using these models by adding an interaction term (cotinine concentration : rs10220464 588 genotype). Proportions of explained variance were calculated by squaring partial correlation coefficients

- 589 of regression model predictors [153]. One sample from one sibling pair was removed from all methylation 590 analyses to prevent confounding due to relatedness.
- 591

592 **Mendelian Randomization and Mediation Analysis**

593 To assess the causal effects of DNA methylation on lung function, we performed one-sample Mendelian 594 randomization analysis. We applied a 2SLS regression to URECA samples with WGS and DNA 595 methylation data (n=285) using ivreg [154]. DNA methylation levels in NECs at the cg03306306 CpG 596 site were first adjusted for methylation PCs 1-3 and used as the endogenous, exposure variable. The 597 adjusted and normalized FEV_1 values from the GWAS were set as the dependent outcome variable. Urine 598 cotinine levels were included as an exogenous covariate (included in both stages). The instrumental 599 variables were chosen from a set of candidate SNPs that were at least nominally associated with 600 cg03306306 methylation with p<0.15. Clustering of pairwise linkage disequilibrium values between these 601 SNPs revealed six distinct haplotypes (S**14 Fig**). To ensure instrument exogeneity, each candidate SNP 602 was tested for association with FEV_1 after conditioning on cg03306306 methylation and urine cotinine, 603 and SNPs associated with p<0.05 were removed from consideration. Of the remaining candidate SNPs, 604 one was chosen from each haplotype, resulting in an instrument composed of 4 SNPs (rs11160777, 605 rs137961671, rs7143936, rs11160776). Instrument relevance was validated using the F test, endogeneity 606 using the Wu-Hausman test, and instrument exogeneity using the Sargon test. We tested two 2SLS 607 models: one where the instrumental variables were included as individual predictors, and another 608 featuring an unweighted allele score of the four instrumental variants to reduce potential bias from weak 609 instruments and/or winner's curse [155,156]. 610 Mediation analysis was conducted with ROBMED [157]. The adjusted and normalized $FEV₁$ 611 residuals were set as the dependent variable, adjusted cg03306306 methylation as the mediator, and

612 rs10220464 as the independent variable. Age at FEV1 measurement, sex, asthma status, ancestry PCs 1-3,

613 and urine cotinine levels were included as covariates. We also performed a secondary mediation analysis

614 without adjusting for asthma status. To identify additional, potential confounders that could invalidate our

634 **Chromatin Interaction Analysis**

635 Chromatin interactions were assessed using promoter capture Hi-C [161,162] in ex vivo human BECs

636 from 8 adult lung donors, including 4 with asthma. The data was processed and analyzed as previously

637 described [72,163]. Chromosomal interactions were evaluated using the CHiCAGO algorithm [164].

638 Interactions with CHiCAGO scores ≥5 were considered significant [164]. Genetic variants within 1 kb of

639 a given interacting fragment were considered part of the chromatin loop. Genes that were not expressed in

640 NECs were not included in the analysis.

641 **DATA AVAILABILITY**

- 643 dbGaP under accession **phs002921.v1.p1**. The URECA gene expression data are available on the Gene
- 644 Expression Omnibus (GEO) under the accession **GSE145505** (NECs) and **GSE96783** (PBMCs). The
- 645 pcHi-C data are available in GEO under the reference series **GSE152550**. The DNA methylation data will
- 646 be deposited to GEO (Morin, et al. A Functional Genomics Pipeline to Identify High-Value Asthma and
- 647 Allergy CpGs in the Human Methylome. medRxiv. 2022:2022.05.19.22275204).
- 648

649 **ACKNOWLEDGEMENTS**

650 We are grateful to all participants and their families who took part in these studies. We would like to

651 extend special thanks to Pieter Faber and the University of Chicago Genomics Facility, as well as to Petra

652 LeBeau and Rebecca Z. Krouse, formerly of Rho Inc., for their respective contributions.

653

654 **FUNDING**

- 655 This work was supported by NIH grants U19 AI62310, HHSN272200900052C, HHSN272201000052I,
- 656 UM1 AI114271, UG3 OD023282, and UM1 AI160040. Site data collection was supported by the
- 657 following NIH grants: RR00052, UL1 TR001079 (Baltimore); M01 RR00533, UL1 RR025771, 1 UL1
- 658 TR001430 (Boston); UL1 TR000150 (Chicago); UL1 TR000451, UL1 TR001105 (Dallas); Ul1
- 659 RR025780 (Denver); UL1 TR000040, M01 RR00071, UL1 RR024156 (New York); UL1 TR000075
- 660 (D.C.); UL1 TR000077 (Cincinnati). M.D. was supported by TL1 TR002388 and T32 HL007605.
- 661

662 **AUTHOR CONTRIBUTIONS**

- 663 M.D., W.W.B., P.B., D.N., G.T.O., J.E.G., D.J.J., C.O. made contributions to the conception and/or
- 664 design of the study. M.D., E.T., and S.C. performed computational analyses. E.T. prepared samples for
- 665 'omic analyses. W.W-S. oversaw 'omic data management. C.M.V. and A.C. oversaw clinical data
- 666 management. J.E.S., D.G., G.T.O., J.E.G., D.J.J., C.O. contributed to interpretation of results. R.A.W.,

667 M.M., G.N.K.H., M.G.S., R.S.G, M.A.G., A.H.L., H.K., M.K., L.B.B., D.S., M.C.A. contributed patient 668 samples and/or data. M.D. wrote the manuscript. All authors read and approved the manuscript. 669

670 **DISCLOSURES**

671 All authors, with the exception of M. Altman and P. Becker, report grants from NIH/NIAID during the 672 conduct of study. M. Dapas, C. Visness, A. Calatroni and P. Becker have nothing to disclose outside the 673 submitted work. C. Ober reports personal fees from American Association of Asthma, Allergy and 674 Immunology, outside the submitted work. M. Altman reports personal fees from Sanofi-Regeneron 675 outside the submitted work. W. Busse reports personal fees from Boston Scientific, Novartis, Glaxo 676 SmithKline, Genentech, Sanofi/Genzyme, AstraZeneca, Teva, Regeneron and Elsevier outside the 677 submitted work. M. Gill reports an honorarium for and support for travel to the 2017 AAAAI meeting 678 during the conduct of study and monetary compensation from the American Academy of Pediatrics for 679 her work teaching the biannual Pediatrics board review course, PREP The Course. K. Hershey reports 680 grants from Adare, during the conduct of the study. D. Jackson reports personal fees from Novartis, 681 Boehringer Ingelheim, Pfizer, Regeneron, AstraZeneca, Sanofi and Vifor Pharma, grants and personal 682 fees from GlaxoSmithKline and grants from NIH/NHLBI, outside the submitted work. M. Kattan reports 683 personal fees from Regeneron, outside the submitted work. R. Gruchalla reports government employment 684 from Center for Biologics Evaluation and Research as well as personal fees from Consulting 685 Massachusetts Medical Society, outside the submitted work. A. Liu reports personal fees from Phadia 686 ThermoFisher as consulting honoraria, grants and non-financial support from ResMed/Propeller Health, 687 non-financial support from Revenio, grants and personal fees from Avillion and personal fees from 688 Labcorp, outside the submitted work. L. Bacharier reports personal fees from GlaxoSmithKline, 689 Genentech/Novartis, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, 690 Sanofi/Regeneron, Vectura and geCircassia and personal fees and non-financial support from 691 Merckoutside the submitted work. J. Gern reports personal fees from AstraZeneca and Gossamer Bio and 692 personal fees and stock options from Meissa Vaccines Inc, outside the submitted work. In addition, Dr.

- 693 Gern has a patent Methods of Propagating Rhinovirus C in Previously Unsusceptible Cell Lines issued,
- 694 and a patent Adapted Rhinovirus C issued. G. O'Connor reports personal fees from AstraZeneca and
- 695 grants from Janssen Pharmaceuticals, outside the submitted work. R. Wood reports grants from DBV,
- 696 Aimmune, Astellas, HAL-Allergy and Regeneron and royalties from Up to Date, outsite the submitted
- 697 work. Dr. Becker's co-authorship of this publication does not necessarily constitute endorsement by the
- 698 National Institute of Allergy and Infectious Diseases, the National Institutes of Health or any other agency
- 699 of the United States government.

700

701 **REFERENCES**

- 702 1. Hole DJ, Watt GC, Davey-Smith G, Hart CL, Gillis CR, Hawthorne VM. Impaired lung 703 function and mortality risk in men and women: findings from the Renfrew and Paisley 704 prospective population study. BMJ. 1996;313(7059):711-5; discussion 5-6.
- 705 2. Schunemann HJ, Dorn J, Grant BJ, Winkelstein W, Jr., Trevisan M. Pulmonary function is 706 a long-term predictor of mortality in the general population: 29-year follow-up of the 707 Buffalo Health Study. Chest. 2000;118(3):656-64.
- 708 3. Mannino DM, Holguin F, Pavlin BI, Ferdinands JM. Risk factors for prevalence of and mortality related to restriction on spirometry: findings from the First National Health and 710 Nutrition Examination Survey and follow-up. Int J Tuberc Lung Dis. 2005;9(6):613-21.
- 711 4. Chinn S, Gislason T, Aspelund T, Gudnason V. Optimum expression of adult lung function 712 based on all-cause mortality: results from the Reykjavik study. Respir Med. 713 2007;101(3):601-9.
- 714 5. Miller MR, Pedersen OF, Lange P, Vestbo J. Improved survival prediction from lung 715 function data in a large population sample. Respir Med. 2009;103(3):442-8.
- 716 6. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later 717 life: a transgenerational cohort analysis. Lancet Respir Med. 2017;5(12):935-45.
- 718 7. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early 719 infancy and lung function by age 22 years: a non-selective longitudinal cohort study. 720 Lancet. 2007;370(9589):758-64.
- 721 8. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory 722 health and disease. Lancet Respir Med. 2013;1(9):728-42.
- 723 9. McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, et al. Patterns of 724 Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med. 725 2016;374(19):1842-52.
- 726 10. Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med. 727 2019;7(4):358-64.
- 728 11. Bisgaard H, Jensen SM, Bonnelykke K. Interaction between asthma and lung function 729 growth in early life. Am J Respir Crit Care Med. 2012;185(11):1183-9.
- 730 12. Duijts L, Reiss IK, Brusselle G, de Jongste JC. Early origins of chronic obstructive lung 731 diseases across the life course. Eur J Epidemiol. 2014;29(12):871-85.
- 732 13. Klimentidis YC, Vazquez AI, de Los Campos G, Allison DB, Dransfield MT, Thannickal 733 VJ. Heritability of pulmonary function estimated from pedigree and whole-genome 734 markers. Front Genet. 2013;4:174.

- 735 14. Wilk JB, Chen TH, Gottlieb DJ, Walter RE, Nagle MW, Brandler BJ, et al. A genome-736 wide association study of pulmonary function measures in the Framingham Heart Study. 737 PLoS Genet. 2009;5(3):e1000429.
- 738 15. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, Obeidat M, et al. Genome-wide 739 association study identifies five loci associated with lung function. Nat Genet. 740 2010;42(1):36-44.
- 741 16. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, et al. Meta-742 analyses of genome-wide association studies identify multiple loci associated with 743 pulmonary function. Nat Genet. 2010;42(1):45-52.
- 744 17. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide 745 association and large-scale follow up identifies 16 new loci influencing lung function. Nat 746 Genet. 2011;43(11):1082-90.
- 747 18. Yao TC, Du G, Han L, Sun Y, Hu D, Yang JJ, et al. Genome-wide association study of 748 lung function phenotypes in a founder population. J Allergy Clin Immunol. 749 2014;133(1):248-55 e1-10.
- 750 19. Loth DW, Soler Artigas M, Gharib SA, Wain LV, Franceschini N, Koch B, et al. Genome-751 wide association analysis identifies six new loci associated with forced vital capacity. Nat 752 Genet. 2014;46(7):669-77.
- 753 20. Wain LV, Shrine N, Artigas MS, Erzurumluoglu AM, Noyvert B, Bossini-Castillo L, et al. 754 Genome-wide association analyses for lung function and chronic obstructive pulmonary 755 disease identify new loci and potential druggable targets. Nat Genet. 2017;49(3):416-25.
- 756 21. Burkart KM, Sofer T, London SJ, Manichaikul A, Hartwig FP, Yan Q, et al. A Genome-757 Wide Association Study in Hispanics/Latinos Identifies Novel Signals for Lung Function. 758 The Hispanic Community Health Study/Study of Latinos. Am J Respir Crit Care Med. 759 2018;198(2):208-19.
- 760 22. Wyss AB, Sofer T, Lee MK, Terzikhan N, Nguyen JN, Lahousse L, et al. Multiethnic 761 meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. 762 Nat Commun. 2018;9(1):2976.
- 763 23. Shrine N, Guyatt AL, Erzurumluoglu AM, Jackson VE, Hobbs BD, Melbourne CA, et al. 764 New genetic signals for lung function highlight pathways and chronic obstructive 765 pulmonary disease associations across multiple ancestries. Nat Genet. 2019;51(3):481-93.
- 766 24. Akenroye AT, Brunetti T, Romero K, Daya M, Kanchan K, Shankar G, et al. Genome-wide 767 association study of asthma, total IgE, and lung function in a cohort of Peruvian children. J 768 Allergy Clin Immunol. 2021. doi: 10.1016/j.jaci.2021.02.035.
- 769 25. Zhu Z, Li J, Si J, Ma B, Shi H, Lv J, et al. A large-scale genome-wide association analysis 770 of lung function in the Chinese population identifies novel loci and highlights shared 771 genetic aetiology with obesity. Eur Respir J. 2021;58(4).

- 772 26. Obeidat M, Hao K, Bosse Y, Nickle DC, Nie Y, Postma DS, et al. Molecular mechanisms 773 underlying variations in lung function: a systems genetics analysis. Lancet Respir Med. 774 2015;3(10):782-95.
- 775 27. Gharib SA, Loth DW, Soler Artigas M, Birkland TP, Wilk JB, Wain LV, et al. Integrative 776 pathway genomics of lung function and airflow obstruction. Hum Mol Genet. 777 2015;24(23):6836-48.
- 778 28. Portas L, Pereira M, Shaheen SO, Wyss AB, London SJ, Burney PGJ, et al. Lung 779 Development Genes and Adult Lung Function. Am J Respir Crit Care Med. 780 2020;202(6):853-65.
- 781 29. Kheirallah AK, Miller S, Hall IP, Sayers I. Translating Lung Function Genome-Wide 782 Association Study (GWAS) Findings: New Insights for Lung Biology. Adv Genet. 783 2016;93:57-145.
- 784 30. Aschard H, Tobin MD, Hancock DB, Skurnik D, Sood A, James A, et al. Evidence for 785 large-scale gene-by-smoking interaction effects on pulmonary function. Int J Epidemiol. 786 2017;46(3):894-904.
- 787 31. Park B, An J, Kim W, Kang HY, Koh SB, Oh B, et al. Effect of 6p21 region on lung 788 function is modified by smoking: a genome-wide interaction study. Sci Rep. 789 2020;10(1):13075.
- 790 32. Kim W, Moll M, Qiao D, Hobbs BD, Shrine N, Sakornsakolpat P, et al. Smoking 791 Interaction with a Polygenic Risk Score for Reduced Lung Function. medRxiv. 2021. doi: 792 10.1101/2021.03.26.21254415:2021.03.26.21254415.
- 793 33. Melbourne CA, Erzurumluoglu AM, Shrine N, Chen J, Tobin MD, Hansell A, et al. 794 Genome-wide gene-air pollution interaction analysis of lung function in 300,000 795 individuals. medRxiv. 2021. doi: 10.1101/2021.06.03.21256376:2021.06.03.21256376.
- 796 34. Miller MD, Marty MA. Impact of environmental chemicals on lung development. Environ 797 Health Perspect. 2010;118(8):1155-64.
- 798 35. Decrue F, Gorlanova O, Usemann J, Frey U. Lung functional development and asthma 799 trajectories. Semin Immunopathol. 2020;42(1):17-27.
- 800 36. He Z, Wu H, Zhang S, Lin Y, Li R, Xie L, et al. The association between secondhand 801 smoke and childhood asthma: A systematic review and meta-analysis. Pediatr Pulmonol. 802 2020;55(10):2518-31.
- 803 37. Thacher JD, Schultz ES, Hallberg J, Hellberg U, Kull I, Thunqvist P, et al. Tobacco smoke 804 exposure in early life and adolescence in relation to lung function. Eur Respir J. 805 2018;51(6).

841 50. Thakur N, Oh SS, Nguyen EA, Martin M, Roth LA, Galanter J, et al. Socioeconomic status 842 and childhood asthma in urban minority youths. The GALA II and SAGE II studies. Am J 843 Respir Crit Care Med. 2013;188(10):1202-9.

- 844 51. Oraka E, Iqbal S, Flanders WD, Brinker K, Garbe P. Racial and ethnic disparities in current 845 asthma and emergency department visits: findings from the National Health Interview 846 Survey, 2001-2010. J Asthma. 2013;50(5):488-96.
- 847 52. Keet CA, Matsui EC, McCormack MC, Peng RD. Urban residence, neighborhood poverty, 848 race/ethnicity, and asthma morbidity among children on Medicaid. J Allergy Clin 849 **Immunol.** 2017;140(3):822-7.
- 850 53. Manrai AK, Funke BH, Rehm HL, Olesen MS, Maron BA, Szolovits P, et al. Genetic 851 Misdiagnoses and the Potential for Health Disparities. N Engl J Med. 2016;375(7):655-65.
- 852 54. Landry LG, Ali N, Williams DR, Rehm HL, Bonham VL. Lack Of Diversity In Genomic 853 Databases Is A Barrier To Translating Precision Medicine Research Into Practice. Health 854 Aff (Millwood). 2018;37(5):780-5.
- 855 55. Pongracic JA, Krouse RZ, Babineau DC, Zoratti EM, Cohen RT, Wood RA, et al. 856 Distinguishing characteristics of difficult-to-control asthma in inner-city children and 857 adolescents. J Allergy Clin Immunol. 2016;138(4):1030-41.
- 858 56. Zoratti EM, Krouse RZ, Babineau DC, Pongracic JA, O'Connor GT, Wood RA, et al. 859 Asthma phenotypes in inner-city children. J Allergy Clin Immunol. 2016;138(4):1016-29.
- 860 57. Gern JE, Visness CM, Gergen PJ, Wood RA, Bloomberg GR, O'Connor GT, et al. The 861 Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, 862 and study population. BMC Pulm Med. 2009;9:17.
- 863 58. Zhou X, Stephens M. Genome-wide efficient mixed-model analysis for association studies. 864 Nat Genet. 2012;44(7):821-4.
- 865 59. Consortium EP, Moore JE, Purcaro MJ, Pratt HE, Epstein CB, Shoresh N, et al. Expanded 866 encyclopaedias of DNA elements in the human and mouse genomes. Nature. 867 2020;583(7818):699-710.
- 868 60. Ma M, Ru Y, Chuang LS, Hsu NY, Shi LS, Hakenberg J, et al. Disease-associated variants 869 in different categories of disease located in distinct regulatory elements. BMC Genomics. 870 2015;16 Suppl 8:S3.
- 871 61. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to 872 **Omnigenic.** Cell. 2017;169(7):1177-86.

873 62. Watanabe K, Stringer S, Frei O, Umicevic Mirkov M, de Leeuw C, Polderman TJC, et al. 874 A global overview of pleiotropy and genetic architecture in complex traits. Nat Genet. 875 2019;51(9):1339-48.

876 63. Schulz H, Ruppert AK, Herms S, Wolf C, Mirza-Schreiber N, Stegle O, et al. Genome-877 wide mapping of genetic determinants influencing DNA methylation and gene expression 878 in human hippocampus. Nat Commun. 2017;8(1):1511. 879 64. Huan T, Joehanes R, Song C, Peng F, Guo Y, Mendelson M, et al. Genome-wide 880 identification of DNA methylation QTLs in whole blood highlights pathways for 881 cardiovascular disease. Nat Commun. 2019;10(1):4267. 882 65. Hannon E, Gorrie-Stone TJ, Smart MC, Burrage J, Hughes A, Bao Y, et al. Leveraging 883 DNA-Methylation Quantitative-Trait Loci to Characterize the Relationship between 884 Methylomic Variation, Gene Expression, and Complex Traits. Am J Hum Genet. 885 2018;103(5):654-65. 886 66. McKennan C, Naughton K, Stanhope C, Kattan M, O'Connor GT, Sandel MT, et al. 887 Longitudinal data reveal strong genetic and weak non-genetic components of ethnicity-888 dependent blood DNA methylation levels. Epigenetics. 2021;16(6):662-76. 889 67. Joubert BR, Felix JF, Yousefi P, Bakulski KM, Just AC, Breton C, et al. DNA Methylation 890 in Newborns and Maternal Smoking in Pregnancy: Genome-wide Consortium Meta-891 analysis. Am J Hum Genet. 2016;98(4):680-96. 892 68. Sikdar S, Joehanes R, Joubert BR, Xu CJ, Vives-Usano M, Rezwan FI, et al. Comparison 893 of smoking-related DNA methylation between newborns from prenatal exposure and adults 894 from personal smoking. Epigenomics. 2019;11(13):1487-500. 895 69. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are 896 more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 897 2010;6(4):e1000888. 898 70. Yao DW, O'Connor LJ, Price AL, Gusev A. Quantifying genetic effects on disease 899 mediated by assayed gene expression levels. Nat Genet. 2020;52(6):626-33. 900 71. Hormozdiari F, van de Bunt M, Segre AV, Li X, Joo JWJ, Bilow M, et al. Colocalization 901 of GWAS and eQTL Signals Detects Target Genes. Am J Hum Genet. 2016;99(6):1245-60. 902 72. Helling BA, Sobreira DR, Hansen GT, Sakabe NJ, Luo K, Billstrand C, et al. Altered 903 transcriptional and chromatin responses to rhinovirus in bronchial epithelial cells from
904 adults with asthma. Commun Biol. 2020;3(1):678. adults with asthma. Commun Biol. $2020;3(1):678$. 905 73. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, et al. 906 ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell. 907 2001;8(4):781-94. 908 74. Aylon Y, Ofir-Rosenfeld Y, Yabuta N, Lapi E, Nojima H, Lu X, et al. The Lats2 tumor 909 suppressor augments p53-mediated apoptosis by promoting the nuclear proapoptotic 910 function of ASPP1. Genes Dev. 2010;24(21):2420-9.

911 75. Wang Y, Godin-Heymann N, Dan Wang X, Bergamaschi D, Llanos S, Lu X. ASPP1 and 912 ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer 913 cells. Cell Death Differ. 2013;20(4):525-34.

- 914 76. Xue H, Li MX. MicroRNA-150 protects against cigarette smoke-induced lung 915 inflammation and airway epithelial cell apoptosis through repressing p53: MicroRNA-150 916 in CS-induced lung inflammation. Hum Exp Toxicol. 2018;37(9):920-8.
- 917 77. Xu F, Xu A, Guo Y, Bai Q, Wu X, Ji SP, et al. PM2.5 exposure induces alveolar epithelial 918 cell apoptosis and causes emphysema through p53/Siva-1. Eur Rev Med Pharmacol Sci. 919 2020;24(7):3943-50.
- 920 78. Song Q, Zhou ZJ, Cai S, Chen Y, Chen P. Oxidative stress links the tumour suppressor p53 921 with cell apoptosis induced by cigarette smoke. Int J Environ Health Res. 2021. doi: 922 10.1080/09603123.2021.1910211:1-11.
- 923 79. Zhao K, Yu M, Zhu Y, Liu D, Wu Q, Hu Y. EGR-1/ASPP1 inter-regulatory loop promotes 924 apoptosis by inhibiting cyto-protective autophagy. Cell Death Dis. 2017;8(6):e2869.
- 925 80. Reynolds PR, Cosio MG, Hoidal JR. Cigarette smoke-induced Egr-1 upregulates 926 proinflammatory cytokines in pulmonary epithelial cells. Am J Respir Cell Mol Biol. 927 2006;35(3):314-9.
- 928 81. Chen ZH, Kim HP, Sciurba FC, Lee SJ, Feghali-Bostwick C, Stolz DB, et al. Egr-1 929 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. 930 PLoS One. 2008;3(10):e3316.
- 931 82. Shen N, Gong T, Wang JD, Meng FL, Qiao L, Yang RL, et al. Cigarette smoke-induced 932 pulmonary inflammatory responses are mediated by EGR-1/GGPPS/MAPK signaling. Am 933 **J Pathol.** 2011;178(1):110-8.
- 934 83. Wang SB, Zhang C, Xu XC, Xu F, Zhou JS, Wu YP, et al. Early growth response factor 1 935 is essential for cigarette smoke-induced MUC5AC expression in human bronchial 936 epithelial cells. Biochem Biophys Res Commun. 2017;490(2):147-54.
- 937 84. Xu F, Cao J, Luo M, Che L, Li W, Ying S, et al. Early growth response gene 1 is essential 938 for urban particulate matter-induced inflammation and mucus hyperproduction in airway
939 epithelium. Toxicol Lett. 2018;294:145-55. epithelium. Toxicol Lett. 2018;294:145-55.
- 940 85. Golebski K, Gorenjak M, Kabesch M, Maitland-Van Der Zee A-H, Melén E, Potočnik U, et al. EGR-1 as a potential biomarker in asthma and proinflammatory responses in airway 942 epithelium. European Respiratory Journal. 2021;58(suppl 65):PA2041.
- 943 86. Wang A, Chiou J, Poirion OB, Buchanan J, Valdez MJ, Verheyden JM, et al. Single-cell 944 multiomic profiling of human lungs reveals cell-type-specific and age-dynamic control of 945 SARS-CoV2 host genes. Elife. 2020;9.

- 981 100. den Dekker HT, Burrows K, Felix JF, Salas LA, Nedeljkovic I, Yao J, et al. Newborn 982 DNA-methylation, childhood lung function, and the risks of asthma and COPD across the 983 life course. Eur Respir J. 2019;53(4).
- 984 101. Imboden M, Wielscher M, Rezwan FI, Amaral AFS, Schaffner E, Jeong A, et al. 985 Epigenome-wide association study of lung function level and its change. Eur Respir J. 986 2019;54(1).
- 987 102. Mukherjee N, Arathimos R, Chen S, Kheirkhah Rahimabad P, Han L, Zhang H, et al. DNA 988 methylation at birth is associated with lung function development until age 26 years. Eur 989 Respir J. 2021;57(4).
- 990 103. Wang T, Wang W, Li W, Duan H, Xu C, Tian X, et al. Genome-wide DNA methylation 991 analysis of pulmonary function in middle and old-aged Chinese monozygotic twins. Respir 992 Res. 2021;22(1):300.
- 993 104. Herrera-Luis E, Li A, Mak ACY, Perez-Garcia J, Elhawary JR, Oh SS, et al. Epigenome-994 wide association study of lung function in Latino children and youth with asthma. Clin 995 Epigenetics. 2022;14(1):9.
- 996 105. Cosin-Tomas M, Bustamante M, Sunyer J. Epigenetic association studies at birth and the origin of lung function development. Eur Respir J. 2021:57(4). origin of lung function development. Eur Respir J. 2021;57(4).
- 998 106. Yang IV, Lozupone CA, Schwartz DA. The environment, epigenome, and asthma. J 999 Allergy Clin Immunol. 2017;140(1):14-23.
- 1000 107. Lin PI, Shu H, Mersha TB. Comparing DNA methylation profiles across different tissues 1001 associated with the diagnosis of pediatric asthma. Sci Rep. 2020;10(1):151.
- 1002 108. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold 1003 Spring Harb Perspect Med. 2022;12(1).
- 1004 109. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. 1005 Epidemiology. 1992;3(2):143-55.
- 1006 110. Li YF, Gilliland FD, Berhane K, McConnell R, Gauderman WJ, Rappaport EB, et al. 1007 Effects of in utero and environmental tobacco smoke exposure on lung function in boys 1008 and girls with and without asthma. Am J Respir Crit Care Med. 2000;162(6):2097-104.
- 1009 111. Gilliland FD, Berhane K, Li YF, Rappaport EB, Peters JM. Effects of early onset asthma 1010 and in utero exposure to maternal smoking on childhood lung function. Am J Respir Crit 1011 Care Med. 2003;167(6):917-24.
- 1012 112. Schultz ES, Litonjua AA, Melen E. Effects of Long-Term Exposure to Traffic-Related Air 1013 Pollution on Lung Function in Children. Curr Allergy Asthma Rep. 2017;17(6):41.
- 1014 113. Kreiner-Moller E, Bisgaard H, Bonnelykke K. Prenatal and postnatal genetic influence on 1015 lung function development. J Allergy Clin Immunol. 2014;134(5):1036-42 e15.

1051 126. Kicic A, de Jong E, Ling KM, Nichol K, Anderson D, Wark PAB, et al. Assessing the 1052 unified airway hypothesis in children via transcriptional profiling of the airway epithelium. 1053 J Allergy Clin Immunol. 2020;145(6):1562-73. 1054 127. Bergougnoux A, Claustres M, De Sario A. Nasal epithelial cells: a tool to study DNA 1055 methylation in airway diseases. Epigenomics. 2015;7(1):119-26. 1056 128. Gergen PJ, Teach SJ, Togias A, Busse WW. Reducing Exacerbations in the Inner City: 1057 Lessons from the Inner-City Asthma Consortium (ICAC). J Allergy Clin Immunol Pract. 1058 2016;4(1):22-6. 1059 129. O'Connor GT, Lynch SV, Bloomberg GR, Kattan M, Wood RA, Gergen PJ, et al. Early-1060 life home environment and risk of asthma among inner-city children. J Allergy Clin 1061 Immunol. 2018;141(4):1468-75. 1062 130. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic 1063 reference values for spirometry for the 3-95-yr age range: the global lung function 2012 1064 equations. Eur Respir J. 2012;40(6):1324-43. 1065 131. Bernert JT, Harmon TL, Sosnoff CS, McGuffey JE. Use of continine immunoassay test 1066 strips for preclassifying urine samples from smokers and nonsmokers prior to analysis by 1067 LC-MS-MS. J Anal Toxicol. 2005;29(8):814-8. 1068 132. Regier AA, Farjoun Y, Larson DE, Krasheninina O, Kang HM, Howrigan DP, et al. 1069 Functional equivalence of genome sequencing analysis pipelines enables harmonized 1070 variant calling across human genetics projects. Nat Commun. 2018;9(1):4038. 1071 133. Kowalski MH, Qian H, Hou Z, Rosen JD, Tapia AL, Shan Y, et al. Use of >100,000 1072 NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium whole genome 1073 sequences improves imputation quality and detection of rare variant associations in 1074 admixed African and Hispanic/Latino populations. PLoS Genet. 2019;15(12):e1008500. 1075 134. Zhang F, Flickinger M, Taliun SAG, In PPGC, Abecasis GR, Scott LJ, et al. Ancestry-1076 agnostic estimation of DNA sample contamination from sequence reads. Genome Res. 1077 2020;30(2):185-94. 1078 135. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation
1079 PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7. 1079 PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7. 1080 136. McKennan C, Naughton K, Stanhope C, Kattan M, O'Connor GT, Sandel MT, et al. 1081 Longitudinal data reveal strong genetic and weak non-genetic components of ethnicity-1082 dependent blood DNA methylation levels. Epigenetics. 2020. doi: 1083 10.1080/15592294.2020.1817290:1-15. 1084 137. Jun G, Flickinger M, Hetrick KN, Romm JM, Doheny KF, Abecasis GR, et al. Detecting 1085 and estimating contamination of human DNA samples in sequencing and array-based 1086 genotype data. Am J Hum Genet. 2012;91(5):839-48.

- 1087 138. Hao W, Storey JD. Extending Tests of Hardy-Weinberg Equilibrium to Structured 1088 Populations. Genetics. 2019;213(3):759-70.
- 1089 139. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo MA, et al. The variant 1090 call format and VCFtools. Bioinformatics. 2011;27(15):2156-8.
- 1091 140. Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of 1092 SAMtools and BCFtools. Gigascience. 2021:10(2). SAMtools and BCFtools. Gigascience. 2021;10(2).
- 1093 141. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A 1094 global reference for human genetic variation. Nature. 2015;526(7571):68-74.
- 1095 142. Bergstrom A, McCarthy SA, Hui R, Almarri MA, Ayub Q, Danecek P, et al. Insights into 1096 human genetic variation and population history from 929 diverse genomes. Science.
1097 2020:367(6484). 2020;367(6484).
- 1098 143. Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in 1099 unrelated individuals. Genome Res. 2009;19(9):1655-64.
- 1100 144. Conomos MP, Miller MB, Thornton TA. Robust inference of population structure for 1101 ancestry prediction and correction of stratification in the presence of relatedness. Genet 1102 Epidemiol. 2015;39(4):276-93.
- 1103 145. Conomos MP, Reiner AP, Weir BS, Thornton TA. Model-free Estimation of Recent 1104 Genetic Relatedness. Am J Hum Genet. 2016;98(1):127-48.
- 1105 146. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship 1106 inference in genome-wide association studies. Bioinformatics. 2010;26(22):2867-73.
- 1107 147. Shringarpure SS, Bustamante CD, Lange K, Alexander DH. Efficient analysis of large 1108 datasets and sex bias with ADMIXTURE. BMC Bioinformatics. 2016;17:218.
- 1109 148. Sofer T, Zheng X, Gogarten SM, Laurie CA, Grinde K, Shaffer JR, et al. A fully adjusted 1110 two-stage procedure for rank-normalization in genetic association studies. Genet 1111 Epidemiol. 2019;43(3):263-75.
- 1112 149. McCaw ZR, Lane JM, Saxena R, Redline S, Lin X. Operating characteristics of the rank-1113 based inverse normal transformation for quantitative trait analysis in genome-wide 1114 association studies. Biometrics. 2020;76(4):1262-72.
- 1115 150. Wang G, Sarkar A, Carbonetto P, Stephens M. A simple new approach to variable selection 1116 in regression, with application to genetic fine mapping. Journal of the Royal Statistical 1117 Society: Series B (Statistical Methodology). 2020;82(5):1273-300.
- 1118 151. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. 1119 Bioinformatics. 2012;28(10):1353-8.

- 1120 152. McKennan C, Nicolae D. Accounting for unobserved covariates with varying degrees of 1121 estimability in high-dimensional biological data. Biometrika. 2019;106(4):823-40.
- 1122 153. Zhang D. A Coefficient of Determination for Generalized Linear Models. The American 1123 **Statistician.** 2017;71(4):310-6.
- 1124 154. Fox J, Kleiber C, Zeileis A. ivreg: Two-Stage Least-Squares Regression with Diagnostics. 1125 https://john-d-fox.github.io/ivreg/2021.
- 1126 155. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for 1127 Mendelian randomization. Stat Methods Med Res. 2017;26(5):2333-55.
- 1128 156. Burgess S, Thompson SG. Use of allele scores as instrumental variables for Mendelian 1129 randomization. International Journal of Epidemiology. 2013;42(4):1134-44.
- 1130 157. Alfons A, Ateş NY, Groenen PJF. A Robust Bootstrap Test for Mediation Analysis.
1131 Organizational Research Methods.0(0):1094428121999096. Organizational Research Methods.0(0):1094428121999096.
- 1132 158. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast 1133 universal RNA-seq aligner. Bioinformatics. 2013;29(1):15-21.
- 1134 159. Law CW, Chen Y, Shi W, Smyth GK. voom: Precision weights unlock linear model 1135 analysis tools for RNA-seq read counts. Genome Biol. 2014;15(2):R29.
- 1136 160. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential 1137 expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 1138 2015;43(7):e47.
- 1139 161. Jager R, Migliorini G, Henrion M, Kandaswamy R, Speedy HE, Heindl A, et al. Capture 1140 Hi-C identifies the chromatin interactome of colorectal cancer risk loci. Nat Commun. 1141 2015;6:6178.
- 1142 162. Mifsud B, Tavares-Cadete F, Young AN, Sugar R, Schoenfelder S, Ferreira L, et al. 1143 Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. 1144 **Nat Genet.** 2015;47(6):598-606.
- 1145 163. Montefiori LE, Sobreira DR, Sakabe NJ, Aneas I, Joslin AC, Hansen GT, et al. A promoter 1146 interaction map for cardiovascular disease genetics. Elife. 2018;7.
- 1147 164. Cairns J, Freire-Pritchett P, Wingett SW, Varnai C, Dimond A, Plagnol V, et al. 1148 CHiCAGO: robust detection of DNA looping interactions in Capture Hi-C data. Genome 1149 Biol. 2016;17(1):127.
- 1150

SUPPORTING INFORMATION

S1 Fig. Whole-genome sequencing depth and coverage. A) Histogram of 1,035 whole-genome sequencing (WGS) samples from APIC and URECA by mean depth of coverage. **B)** Histogram of WGS samples based on proportion of genome covered at 20x, 25x, and 30x depth. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study. **S1 Table. Post-QC sequencing call concordance between replicates.** Variant call concordance between three pairs of replicate samples, by variant type and cohort allele frequency. SNPs, single nucleotide polymorphisms; MAF, minor allele frequency; InDels, insertions and deletions. **S2 Table. FEV1-associated variants in chr14q32.33.** All variants in chr14q32.33 associated 1167 with FEV₁ (% predicted) with p<1x10⁻⁵ (n=82) in GWAS of 896 participants from APIC & URECA. N, number of genotyped individuals. MAF, minor allele frequency; 95% CI, 95% 1169 confidence interval; SE, standard error; P, P-value (Wald); FEV₁, forced expiratory volume in one second; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study. **1174 S2 Fig. Distribution of lung function measures by study. A) Distribution of FEV₁ (%)** predicted) in APIC and URECA. **B)** Distribution of FEV1/FVC in APIC and URECA. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma 1177 study. $FEV₁$, forced expiratory volume in one second; FVC, forced vital capacity. **S3 Fig. P-value distributions of GWAS results.** Quantile-quantile plots of the GWAS results 1181 with corresponding genomic control factors (lambda) are shown for A) $FEV₁$ (% predicted) and 1182 B) FEV₁/FVC. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity. **S4 Fig. Fine-mapping results for FEV1 (% predicted) at the** *TDRD9* **locus.** The X-axis shows the chromosome position on chromosome 14. The Y-axis is the posterior inclusion probability (PIP). Variants highlighted in red represent a credible set, in which there is a 95% probability that at least one of the variants is causal. FEV₁, forced expiratory volume in one second. **S5 Fig. Genome-wide association results without adjustment for asthma.** GWAS 1192 Manhattan plots for A) FEV₁ and B) FEV₁/FVC ratio, without adjustment for asthma status. The 1193 horizontal red line indicates genome-wide significance (p ≤ 2.5x10⁻⁸). The dotted horizontal blue

line indicates p=1x10−5 . Variants colored in grey are the GWAS results with asthma adjustment. 1195 FEV₁, forced expiratory volume in one second; FEV₁/FVC, ratio of FEV₁ to forced vital capacity.

- 1198 **S6 Fig. Replication of FEV₁ GWAS SNPs.** Association statistics for previously identified FEV₁ GWAS SNPs [23]. 64 out of 70 previously identified SNPs were genotyped in APIC & URECA. GWAS, genome-wide association study; SNP, single nucleotide polymorphism; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study. FEV₁, forced expiratory volume in one second.
-

S7 Fig. Replication of FEV₁/FVC GWAS SNPs. Association statistics for previously identified 1206 FEV₁/FVC GWAS SNPs [23]. 112 out of 117 previously identified SNPs were genotyped in APIC & URECA. GWAS, genome-wide association study; SNP, single nucleotide polymorphism; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment 1209 and Childhood Asthma study. FEV_1 , forced expiratory volume in one second; FVC, forced vital capacity.

-
-

S3 Table. MeQTL analysis results and associations with FEV₁. All CpG sites where DNA methylation levels in NECs at age 11 in URECA were associated with rs10220464 at FDR<0.05 1215 are shown with their corresponding associations with $FEV₁$. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence 1217 interval; FEV₁, forced expiratory volume in one second; URECA, Urban Environment and Childhood Asthma study.

 S8 Fig. NicAlert Results by Study. Distribution of urine cotinine levels, as measured using NicAlert immunochromatographic assays, which report results on a scale of 0-6 according to the labeled concentration ranges. Proportions were calculated relative to the number of samples with available NicAlert results. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.

S9 Fig. DNA methylation at cg03306306 by smoking exposure. DNA methylation levels at cg03306306 are shown by rs10220464 genotype in URECA participants with low and high 1230 smoking exposures in (A) NECs at age 11 and (B) PBMCs at age 7. FEV₁ (% predicted) are also shown by cg03306306 DNA methylation levels in URECA participants with low and high smoking exposures in (**C**) NECs at age 11 and (**D**) PBMCs at age 7. NECs, nasal epithelial 1233 cells; PBMCs, peripheral blood mononuclear cells; $FEV₁$, forced expiratory volume in one second; URECA, Urban Environment and Childhood Asthma study.

-
-

S10 Fig. Genotype associations with FEV₁ by smoking exposure. FEV₁ (% predicted) are shown by rs10220464 genotype in APIC & URECA participants with low and high smoking 1239 exposures according to urine cotinine levels. $FEV₁$, forced expiratory volume in one second; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.

S4 Table. **rs10220464 eQTL analysis results.** Results of eQTL analyses in NECs and PBMCs with rs10220464 for all genes within 1 Mb in URECA. Gene expression was measured in counts 1246 per million mapped reads. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear cells; URECA, Urban Environment and Childhood Asthma study.

1252 S11 Fig. PPP1R13B expression in NECs vs. smoking exposure, FEV₁. PPP1R13B expression in NECs at age 11 was not associated with smoking exposure at age 10 (**A**) nor with 1254 FEV₁ (% predicted) at age 10 (B) in URECA. NECs, nasal epithelial cells; FEV₁, forced expiratory volume in one second; URECA, Urban Environment and Childhood Asthma.

1258 **S5 Table. Chromatin interactions with FEV₁-associated SNPs.** Bait and target fragments refer to mapped Hi-C restriction fragments on chr14 (hg38) for gene promoters and putative 1260 enhancers, respectively. FEV₁ SNPs refer to number of FEV₁-associated variants (p<1x10⁻⁵) 1261 within 1kb of target fragment. SNPs, single nucleotide polymorphisms; FEV₁, forced expiratory volume in one second.

S6 Table. Age at used lung function measure in URECA. URECA, Urban Environment and 1266 Childhood Asthma study; FEV_1 , forced expiratory volume in one second; FVC, forced vital 1267 capacity.

S7 Table. Study samples. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study; WGS, whole-genome sequencing; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear cells.

1274
1275 **S12 Fig. Data availability across APIC and URECA.** Data availability for measures used in 1276 this study are shown for all sequenced samples. Each row represents a pattern of available a this study are shown for all sequenced samples. Each row represents a pattern of available and 1277 missing data, with green squares indicating available data and grey squares indicating missing
1278 data. Total counts of available data points for each variable are listed across the top of the 1278 data. Total counts of available data points for each variable are listed across the top of the 1279 figure. Total counts for each data availability pattern are listed along the right. figure. Total counts for each data availability pattern are listed along the right.

-
-

S13 Fig. Transitions/transversions vs. quality/depth in WGS variant calls. The

transition/transversion ratio (TS/TV) is plotted against the variant call quality/depth metric (QD) 1284 across all WGS SNP calls in APIC & URECA. Sites with QD less than 4 or greater than 34 were
1285 removed from consideration in this study. SNPs, single nucleotide polymorphisms; WGS, wholeremoved from consideration in this study. SNPs, single nucleotide polymorphisms; WGS, whole-genome sequencing; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.

S14 Fig. Intercorrelation of Mendelian randomization candidate instrument SNPs in

URECA. Instrumental variables were chosen from a set of candidate SNPs that were at least nominally associated with cg03306306 methylation with p<0.15. The correlation values between these SNPs are shown, clustered using Ward's method. The four SNPs used for the instrument are highlighted. URECA, Urban Environment and Childhood Asthma.

S8 Table. Additional phenotypic, socioeconomic, and environmental data. Additional

variables examined for potential confounding in mediation analyses for APIC & URECA. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.

S15 Fig. Intercorrelation of phenotypes and environmental variables in APIC & URECA.

1304 The correlations are shown between FEV_1 (% predicted), smoking exposure (NicAlert), the

1305 primary the lead $FEV₁$ SNP rs10220464, DNA methylation at cg03306306, 11 environmental

exposures, and 2 socioeconomic indicators, clustered using Ward's method. APIC, Asthma

Phenotypes in the Inner City study; exp., exposure; URECA, Urban Environment and Childhood

Asthma.

DNA Methylation: cg03306306

PBMCs

DNA Methylation: cg03306306

S1 Table. Post-QC sequencing call concordance between replicates.

Variant call concordance between three pairs of replicate samples, by variant type and cohort allele frequency. SNPs, single nucleotide polymorphisms; MAF, minor allele frequency; InDels, insertions and deletions.

S2 Table. FEV1-associated variants in chr14q32.33

All variants in chr14q32.33 associated with FEV₁ (% predicted) with p<1x10⁻⁵ (n=82) in GWAS of 896 participants from APIC & URECA. N, number of genotyped individuals. MAF, minor allele frequency; 95% CI, 95% confidence interval; SE, standard error; P, P-value (Wald); FEV₁, forced expiratory volume in one second; APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.

S3 Table. **MeQTL analysis results and associations with FEV1**

All CpG sites where DNA methylation levels in NECs at age 11 in URECA were associated with rs10220464 at FDR<0.05 are shown with their corresponding associations with FEV1. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; FEV₁, forced expiratory volume in one second; URECA, Urban Environment and Childhood Asthma study.

S4 Table. **rs10220464 eQTL analysis results**

Results of eQTL analyses in NECs and PBMCs with rs10220464 for all genes within 1 Mb in URECA. Gene expression was measured in counts per million mapped reads. The FDR-adjusted P-values (FDR Q) correspond to a 5% false-discovery rate. FDR, false discovery rate; 95% CI, 95% confidence interval; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear cells; URECA, Urban Environment and Childhood Asthma study.

S5 Table. Chromatin interactions with FEV1-associated SNPs

Bait and target fragments refer to mapped Hi-C restriction fragments on chr14 (hg38) for gene promoters and putative enhancers, respectively. FEV₁ SNPs refer to number of FEV₁-associated variants (p <1x10⁻⁵) within 1kb of target fragment. SNPs, single nucleotide polymorphisms; FEV₁, forced expiratory volume in one second.

S6 Table. Age at used lung function measure in URECA

URECA, Urban Environment and Childhood Asthma study; FEV₁, forced expiratory volume in one second; FVC, forced vital capacity.

S7 Table. Study samples

APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study; WGS, whole-genome sequencing; NECs, nasal epithelial cells; PBMCs, peripheral blood mononuclear cells.

S8 Table. Additional phenotypic, socioeconomic, and environmental data

Additional variables examined for potential confounding in mediation analyses for APIC & URECA. APIC, Asthma Phenotypes in the Inner City study; URECA, Urban Environment and Childhood Asthma study.

 \blacksquare \geq 20x \blacksquare \geq 25x \blacksquare \geq 30x

Expected $-log_{10}(p)$

β (95% CI)

β (95% CI)

NECs PBMCs

Cotinine concentration (ng/mL)

 $log₂(CPM)$

QUAL / DEPTH

